Guidant Considers CRT Coverage Strategy After Study Shows Mortality Benefit
This article was originally published in The Gray Sheet
Executive Summary
Guidant plans to accelerate talks with CMS in late 2004 as it gauges whether to pursue a Medicare national coverage decision for cardiac resynchronization therapy (CRT) devices
You may also be interested in...
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
Expanded ICD Patient Pool Augured By New Sub-Studies, Design Features
Cardiac rhythm management companies expect their investments in large randomized, controlled trials to spur increased adoption of ICDs this year